Rosuvastatin 20 mg once daily bedtime. 2 months
Checking Date & Time
Reading File
The query is brief and could mean several things. Let me clarify before proceeding.
Asking for Preferences
What would you like to know about Rosuvastatin 20 mg OD bedtime for 2 months?
Finding Sources
Finding Sources
Searching PubMed
rosuvastatin adverse effects safety
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Here is a comprehensive overview of the side effects and safety profile of Rosuvastatin 20 mg once daily at bedtime.
Rosuvastatin 20 mg — Side Effects & Safety Profile
Rosuvastatin 20 mg is classified as a high-intensity statin (alongside rosuvastatin 40 mg and atorvastatin 40–80 mg). Its long half-life (~19 hours) means bedtime dosing offers no pharmacokinetic advantage over other times of day (unlike shorter-acting statins), but it is acceptable.
1. Musculoskeletal Effects (Most clinically important)
| Effect | Frequency | Action |
|---|---|---|
| Myalgia / muscle aches | Up to 10–20% (complaints) | Reassess; many are nocebo-related |
| Asymptomatic CK elevation | ~5% | No action if <10× ULN and asymptomatic |
| Symptomatic myopathy (pain + weakness) | <0.1% | Stop statin |
| Rhabdomyolysis | <0.1% (0–2.2 per 1000 person-years) | Stop immediately; hospitalise; hydrate |
Up to 75–80% of patients who report statin intolerance can actually tolerate a statin when given blinded — the "nocebo" effect accounts for a significant proportion of reported muscle symptoms. — Goldman-Cecil Medicine
Red flags requiring immediate cessation: severe muscle pain/weakness, or dark/tea-coloured urine (myoglobinuria).
Risk factors for myopathy:
- Reduced GFR / CKD
- Hypothyroidism
- Genetic variant in SLCO1B1 (encodes OATP1B1 transporter)
- Drug interactions (see below)
2. Hepatic Effects
- Mild AST/ALT elevation (up to 3× ULN): occurs in some patients; often transient and not associated with clinical hepatotoxicity — can continue with monitoring.
- Persistent ALT/AST >3× ULN or jaundice / ALT >5× ULN: stop the drug, evaluate for other causes.
- Patients with underlying liver disease or heavy alcohol use are at higher risk.
Monitoring: Baseline LFTs → recheck at 1–2 months → then every 12 months if stable. — Katzung's Pharmacology, 16th Ed.
3. New-Onset Diabetes
- Small but significant increase in type 2 diabetes incidence, particularly in patients with pre-existing insulin resistance, obesity, or prediabetes.
- Fasting glucose increases minimally in most; a smaller subset develop frank insulin resistance.
- Management: Continue statin (cardiovascular benefit outweighs risk), encourage weight loss, physical activity, and treat diabetes if it develops. — Goldman-Cecil Medicine
4. CNS / Other Effects
- Infrequent: headache, fatigue, dizziness
- Rare: hemorrhagic stroke (slightly increased signal, particularly at high doses in patients with prior stroke)
- GI: mild — nausea, constipation, dyspepsia (uncommon)
- Dermatological: rash, urticaria (rare)
5. Drug Interactions (Rosuvastatin-specific)
Rosuvastatin is metabolised by CYP2C9 (not CYP3A4 like simvastatin/atorvastatin), so it is less affected by macrolide antibiotics, azole antifungals, and grapefruit juice. However:
| Interacting Drug | Effect |
|---|---|
| CYP2C9 inhibitors (ketoconazole, metronidazole, amiodarone, cimetidine, sulfinpyrazone) | ↑ Rosuvastatin plasma levels → ↑ myopathy risk |
| Cyclosporine | Significantly ↑ rosuvastatin levels |
| Fibrates (especially gemfibrozil) | ↑ Myopathy/rhabdomyolysis risk |
| Antacids (aluminium/magnesium) | May reduce rosuvastatin absorption |
| Warfarin | Rosuvastatin may ↑ INR |
6. Monitoring Summary at 2 Months
| Parameter | Recommendation |
|---|---|
| Fasting lipid panel | Check to assess LDL response |
| LFTs (AST/ALT) | Recheck at 1–2 months post initiation |
| CK | Only if muscle symptoms present; not routine |
| Fasting glucose / HbA1c | Especially in pre-diabetic patients |
| Symptoms | Ask specifically for muscle pain, weakness, dark urine |
Recent Evidence Note
A 2026 Lancet meta-analysis (CTT Collaboration, PMID: 41655587) reassessed adverse effects attributed to statins in blinded RCTs — confirming that many labelled side effects have significant nocebo contributions and that the absolute risks of serious harms (myopathy, hepatotoxicity) are low relative to cardiovascular benefits.
Sources: Katzung's Basic & Clinical Pharmacology 16th Ed. | Goldman-Cecil Medicine | Bradley & Daroff's Neurology | Fitzpatrick's Dermatology | Cholesterol Treatment Trialists Meta-Analysis 2026 (PMID: 41655587)
This is a shared conversation. Sign in to Orris to start your own chat.